Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bristol Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces Dividend Increase
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.